ArticleAAPS PharmSciTech2026
A Quality-by-Design Approach Based Formulation, Optimization, In Vitro and Ex Vivo Evaluation of Delafloxacin-Loaded Ethosomal Gel.
Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current work aims to fabricate and examine a delafloxacin (DFX)-loaded ethosomal (ETHs) gel for improved topical delivery and improved antibacterial efficiency against skin infections. ETHs were prepared using the cold method followed by two-stage homogenization, involving vesicle fabrication and subsequent gel conversion. A Quality by Design framework was employed, with initial screening using a fractional factorial design and optimization through a Box-Behnken design. Entrapment efficiency (EnE), Vesicle size, and PDI were chosen as critical quality attributes. The optimized nanoformulation was evaluated for size, morphology, drug release, cytotoxicity, irritation potential, ex vivo studies antimicrobial activity, and skin safety. The optimized DFX-ETHs exhibited a vesicle size of 263.6 ± 3 nm, zeta potential of - 5.99 ± 1.466 mV, PDI of 0.173 ± 0.019, and EnE of 90.17 ± 0.14%. FE-SEM confirmed globular vesicles with a smooth surface. The formulation showed sustained drug release following Weibull kinetics. Cytotoxicity studies on NIH/3T3 cells and irritation studies using HET-CAM and rat skin models confirmed the cytocompatible and non-irritant nature of the formulation. Enhanced antimicrobial activity against Staphylococcus aureus and Cutibacterium acnes was observed compared to DFX dispersion. The ex vivo studies results showed that the ETHs formulation significantly improved drug permeation relative to the free DFX. The results demonstrate that ethosomal gel systems are a potential and safe carrier for the topical application of DFX, offering improved antibacterial efficacy against bacterial skin infections.
Indexed as
Identifiers
42026395What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.